Meth is most common drug in overdose deaths in chunk of US
Fentanyl is driving drug overdose deaths in the U.S. overall, but in nearly half of the country, it’s a different story. Meth is the bigger killer, a new government report shows. Source: Meth is most common drug in overdose deaths in chunk of...
read moreMeth Deaths Soar in Hawaii Even As Opioids Grab Public Attention
Meth-related overdose fatalities have significantly outpaced other drug overdose deaths in the the past five years. But has anyone noticed? Source: Meth Deaths Soar in Hawaii Even As Opioids Grab Public...
read moreMeth in the Miami Valley: Drug coming back more addictive, powerful
Source: Meth in the Miami Valley: Drug coming back more addictive, powerful
read moreBinding Methamphetamine to Release People from Addiction
InterveXion is a privately-held clinical-stage biopharmaceutical company developing novel product candidates for the treatment of addiction disorders. Our lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine, which acts by re-partitioning methamphetamine away from its sites of action in the CNS. IXT-m200 has received US FDA Fast Track Designation, and is being studied in an ongoing Phase 2 proof-of-concept study (STAMPOUT; NCT03336866). We are also developing a novel vaccine (IXT-v100) against methamphetamine, which is in Preclinical Development.
Meth is most common drug in overdose deaths in chunk of US
Fentanyl is driving drug overdose deaths in the U.S. overall, but in nearly half of the country, it’s a different story. Meth is the bigger killer, a new government report shows. Source: Meth is most common drug in overdose deaths in chunk of...
read moreMeth Deaths Soar in Hawaii Even As Opioids Grab Public Attention
Meth-related overdose fatalities have significantly outpaced other drug overdose deaths in the the past five years. But has anyone noticed? Source: Meth Deaths Soar in Hawaii Even As Opioids Grab Public...
read moreMeth in the Miami Valley: Drug coming back more addictive, powerful
Source: Meth in the Miami Valley: Drug coming back more addictive, powerful
read moreDeveloping Novel Therapeutics for Addiction
InterveXion is a privately-held clinical-stage biopharmaceutical company developing novel product candidates for the treatment of addiction disorders. Our lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine, which acts by re-partitioning methamphetamine away from its sites of action in the CNS. IXT-m200 is being studied in an upcoming Phase 2 proof-of-concept study (STAMPOUT). We are also developing a novel vaccine (IXT-v100) against methamphetamine.